Rapid and POCT in Infectious Space Systems Market Size, Share, Growth, Trends, and Global Industry Analysis: By Technology (Lateral Flow Immunoassay, Agglutination Test, Flo-through Test, Molecular Diagnostics, Others), By Disease (HIV POC, Clostridium Difficile POC, HBV POC, Pneumonia, Respiratory Syncytial Virus POC, HPV POC, MRSA POC, TB & Drug Resistant TB POC, HSV POC, COVID-19, Others), By End-use (Clinics, Hospitals, Home, Laboratory), and Region Forecast 2020-2031

Rapid and POCT in Infectious Disease Space Systems Market size was valued at US$ 3,400 million in 2024 and is expected to reach US$ 5,900 million by 2031, growing at a significant CAGR of 8.6% from 2025-2031. Moreover, the U.S. Rapid and POCT in Infectious Disease Space Systems Market is projected to grow significantly, reaching an estimated value of US$ 2,000 million by 2031. The market for infectious diseases is undergoing a transformative shift. With healthcare systems facing unpredictable outbreaks, there’s an urgent demand for diagnostic tools that are portable, easy to use, and provide results in real time. POCT removes dependency on centralized labs, enabling faster clinical decision-making and timely treatment interventions. This decentralization is especially critical in rural, low-resource, and emergency settings.

As the need for mass screening, outbreak containment, and proactive disease monitoring grows, the relevance of POCT becomes deeply entrenched in both public and private healthcare models, paving the way for a new era of responsive and accessible diagnostics. The demand for efficient infectious disease diagnosis is no longer limited to clinical labs; it now extends to community clinics, mobile health units, and even individual households. Consumers are increasingly aware of health risks and prefer convenient testing options, particularly for recurrent infections like flu or STIs. Technological advances are enabling this shift, bridging lab precision with field simplicity. Global health programs, coupled with private innovation, are prioritizing easy-to-deploy formats that function across geographies and income levels. In this evolving ecosystem, POCT stands at the convergence of public health urgency, medical innovation, and patient-centric care.

Facts & Figures

• Healthcare professionals increasingly rely on rapid tests during outbreaks to guide immediate clinical action.
• Molecular POCT is gaining traction due to its ability to detect infections that traditional kits may miss.
• Public health campaigns are using POCT to screen high-risk populations in remote or underserved areas.
• Patient trust in self-administered tests has improved as packaging, instructions, and accuracy have advanced.

key Developments:

• In May 2025, Abbott received CE mark for its triple rapid test detecting COVID-19, Flu A/B, and RSV at point-of-care settings.
• In April 2025, QuidelOrtho introduced its Sofia® POCT platform expansion to support higher-volume infectious disease testing in clinics.
• In March 2025, Cepheid launched Xpert® MTB-XDR to support rapid, decentralized testing for drug-resistant TB in Asia and Africa.

Rapid and POCT in Infectious Space Systems Market Segmentation:

Based on the technology:

• Lateral Flow Immunoassay
• Agglutination Test
• Flow-through test/Immunoconcentration Assay
• Molecular Diagnostics
• Others

Lateral flow immunoassays (LFIA) lead the technology segment due to their operational simplicity, quick results, and low cost. These tests are ideal for frontline settings where lab access is limited. LFIA is widely used for a range of infections, including flu, HIV, and COVID-19. Their portability, minimal equipment requirements, and visual result interpretation make them highly accessible across healthcare tiers. The format has also adapted to accommodate dual-marker and multiplex testing, enhancing diagnostic capability. Continued innovation in sensitivity and ease of use has kept LFIA relevant despite the rise of molecular alternatives, especially in public health screening and community care.

Based on the disease:

• HIV POC
• Clostridium Difficile POC
• HBV POC
• Pneumonia Or Streptococcus Associated Infections
• Respiratory Syncytial Virus (RSV) POC
• HPV POC
• Influenza/Flu POC
• HCV POC
• MRSA POC
• TB & Drug-resistant TB POC
• HSV POC
• COVID-19
• Other Infectious Diseases

HIV point-of-care testing stands as the leading segment, driven by global health mandates focused on early detection and treatment linkage. Rapid HIV tests enable same-day diagnosis and reduce patient drop-off rates between testing and care. They are essential tools in outreach programs targeting high-risk and remote populations. With the growing availability of self-test kits and mobile clinic formats, HIV POC testing is expanding beyond traditional settings. Innovations now allow dual detection of HIV strains and integration with digital reporting tools. These factors collectively make HIV testing not just a medical need, but a strategic component in global disease elimination goals.

Based on the end use:

• Clinics
• Hospitals
• Home
• Assisted Living Healthcare Facilities
• Laboratory

Hospitals and diagnostic laboratories are the primary end-users of rapid and POCT technologies for infectious diseases. These facilities rely heavily on timely test results to manage critical infections and reduce transmission within clinical settings. POCT solutions enhance their ability to triage patients, initiate treatment quickly, and improve infection control protocols. Especially in emergency and outpatient departments, rapid diagnostics play a vital role in accelerating decision-making and streamlining workflow. With growing emphasis on integrated care and value-based outcomes, hospitals are adopting advanced POCT formats that offer lab-comparable precision. Their central role in outbreak response and surveillance makes them the dominant segment in this market.